Why Amylyx is pulling ALS drug Relyvrio from US market after study
Release time：2024-05-21 11:23:50 Source：Culture Channel news portal
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
- Previous：Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
- Next：Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
Related articles
- Cruise worker 'murders newborn son on board ship': Shocked co
- TJ Maxx job applicant really wants to to work at the store
- China releases reports on budgets, national economic and social development plans
- China launches new relay satellite for Earth
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
- Russia detains 3 more suspects involved in Moscow terror attack
- Raymond scores late in 3rd and OT to keep Red Wings playoffs alive with 5
- Two Moscow concert hall attackers enter Türkiye briefly
- Four people killed in a house explosion in southwestern Missouri
- Capitals beat the Bruins 2
- Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
- TJ Maxx job applicant really wants to to work at the store
- 2 injured in restaurant blast in China's Jiangsu
- Belarus, Azerbaijan to strengthen bilateral cooperation
- Verona confirms Serie A status for another year after beating Salernitana
- China unveils plan on equipment renewal, trading
- Raymond scores late in 3rd and OT to keep Red Wings playoffs alive with 5
- China to enhance coordination with Arab League: Chinese FM
- Celebrity birthdays for the week of May 26
- Biden warns Netanyahu future US support for Israel depends on steps to protect civilians
Random recommendation
- Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Culture Channel news portal sitemap